Protection of mice by a protease inhibitor, aprotinin, against lethal Sendai virus pneumonia.
Proteolytic activation of Sendai virus in the lungs of mice is necessary to cause pneumopathogenicity. Using Sendai virus-infected lung block cultures, protease inhibitors were tested for their antiviral effect by examining inhibition of proteolytic activation. Among the inhibitors tested, a serine protease, aprotinin, was shown to be most effective. In vivo protection experiments demonstrated that aprotinin, when administered intranasally, could confer protection on mice against lethal Sendai virus pneumonia through the same mechanism as observed in the in vitro system. The present study provides an experimental basis for the use of protease inhibitors as antiviral drugs.
Hayashi
T
T
Department of Microbiology, Kobe University School of Medicine, Hyogo, Japan.
Hotta
H
H
Itoh
M
M
Homma
M
M
D000818:Animals; D000998:Antiviral Agents; D007611:Aprotinin / Q000627:therapeutic use*; D008168:Lung / Q000382:microbiology*; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010222:Parainfluenza Virus 1, Human / Q000187:drug effects / Q000502:physiology*; D018184:Paramyxoviridae Infections / Q000517:prevention & control*; D011024:Pneumonia, Viral / Q000517:prevention & control*; D011480:Protease Inhibitors / Q000627:therapeutic use*; D014775:Virus Activation / Q000187:drug effects; D014779:Virus Replication / Q000187:drug effects*
D000998:Antiviral Agents; D011480:Protease Inhibitors; D007611:Aprotinin